Please login to the form below
Cytokinetics
This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.
Amgen agrees to take Cytokinetics' heart failure drug into phase III
originator, Cytokinetics, which has been waiting for the big biotech to make a decision for several weeks. ... Cytokinetics said recently that meetings have been held with both the FDA and EMA to discuss the design of the outcomes study, which is due to
Latest news
-
Biogen buys into Ionis' nusinersen after positive phase III trial
Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months”
-
Roche buys rare disease firm Trophos in €470m deal
SMA therapy in development at Cytokinetics, while Biogen Idec and Isis Pharmaceuticals are also developing ISIS-SMNRx for the disease, a drug due to enter phase III soon.
-
Astellas forges $675m muscle alliance with Cytokinetics
Astellas has signed a major expansion of its collaboration with US biotech Cytokinetics to include neuromuscular diseases. ... It works in a similar way to Cytokinetics' tirasemtiv which is already in phase II trials for amyotrophic lateral sclerosis (ALS
-
Amgen drug misses endpoint in acute heart failure trial
A drug in development by Amgen and Cytokinetics to treat symptoms of heart failure has missed its primary endpoint in a phase II trial.
-
Amgen buys US rights to Servier’s Procoralan
It is the most advanced drug candidate coming out of Amgen's collaboration with Cytokinetics signed in 2006. “
More from news
Approximately 4 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
-
Deal Watch July 2016
Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and
-
Astellas: Ten years young
option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.
-
Heart failure therapy embarks on a new era
In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.
-
Deal Watch table for December 2014
Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Great salary and benefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
-
Senior Medical Writer
-
Great salary and bebefits
- Account Manager – Med Comms – London
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Programme Executive
-
Salary TBC
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
Subscribe to our email news alerts
PMHub
Cello Health Insight
Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...
Latest intelligence
- No Voice, No Choice
- Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
Quick links
Infographics
